Market Research Logo

Eosinophilic Esophagitis - Pipeline Review, H2 2015

Eosinophilic Esophagitis - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Eosinophilic Esophagitis - Pipeline Review, H2 2015’, provides an overview of the Eosinophilic Esophagitis’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Eosinophilic Esophagitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Eosinophilic Esophagitis and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Eosinophilic Esophagitis
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Eosinophilic Esophagitis and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Eosinophilic Esophagitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Eosinophilic Esophagitis pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Eosinophilic Esophagitis
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Eosinophilic Esophagitis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Eosinophilic Esophagitis Overview
Therapeutics Development
Pipeline Products for Eosinophilic Esophagitis - Overview
Eosinophilic Esophagitis - Therapeutics under Development by Companies
Eosinophilic Esophagitis - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Eosinophilic Esophagitis - Products under Development by Companies
Eosinophilic Esophagitis - Companies Involved in Therapeutics Development
Allergan Plc
DBV Technologies S.A.
Dr. Falk Pharma GmbH
Novartis AG
Receptos, Inc.
Regeneron Pharmaceuticals, Inc.
Shire Plc
Eosinophilic Esophagitis - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Allergen for Milk Allergy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
budesonide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
budesonide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
dectrekumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
dupilumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
EUR-1100 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Qi-406 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RPC-4046 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Eosinophilic Esophagitis - Recent Pipeline Updates
Eosinophilic Esophagitis - Dormant Projects
Eosinophilic Esophagitis - Product Development Milestones
Featured News & Press Releases
Oct 03, 2014: Receptos Announces First Patient Treated With Anti-Interleukin-13 Antibody in Phase 2 Trial for Eosinophilic Esophagitis
Sep 25, 2014: Meritage Pharma Announces Positive Results of Oral Budesonide Suspension for Treatment of Eosinophilic Esophagitis in Adolescent and Adult Patients
Jul 21, 2014: High-dose fluticasone effective against eosinophilic esophagitis
May 13, 2014: DBV Technologies Announces Clinical Trial Agreement to Develop a Treatment for Milk-Induced Eosinophilic Esophagitis in Children
Aug 13, 2012: Meritage Initiates Clinical Trial of Oral Budesonide Suspension for Adolescent and Adult Patients with Eosinophilic Esophagitis
May 10, 2011: Meritage Pharma Reports Positive Phase IIb Data for Oral Budesonide Suspension in Pediatric Patients with Eosinophilic Esophagitis
May 10, 2011: Meritage Reports Positive Phase IIb Data for Oral Budesonide Suspension in Pediatric Patients With Eosinophilic Esophagitis
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Eosinophilic Esophagitis, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Products under Development by Companies, H2 2015
Eosinophilic Esophagitis - Pipeline by Allergan Plc, H2 2015
Eosinophilic Esophagitis - Pipeline by DBV Technologies S.A., H2 2015
Eosinophilic Esophagitis - Pipeline by Dr. Falk Pharma GmbH, H2 2015
Eosinophilic Esophagitis - Pipeline by Novartis AG, H2 2015
Eosinophilic Esophagitis - Pipeline by Receptos, Inc., H2 2015
Eosinophilic Esophagitis - Pipeline by Regeneron Pharmaceuticals, Inc., H2 2015
Eosinophilic Esophagitis - Pipeline by Shire Plc, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Eosinophilic Esophagitis Therapeutics - Recent Pipeline Updates, H2 2015
List of Figures
Number of Products under Development for Eosinophilic Esophagitis, H2 2015 7
Number of Products under Development by Companies, H2 2015 8
Comparative Analysis by Clinical Stage Development, H2 2015 10
Assessment by Monotherapy Products, H2 2015 20
Number of Products by Targets, H2 2015 21
Number of Products by Stage and Targets, H2 2015 21
Number of Products by Mechanism of Actions, H2 2015 23
Number of Products by Stage and Mechanism of Actions, H2 2015 23
Number of Products by Routes of Administration, H2 2015 25
Number of Products by Stage and Routes of Administration, H2 2015 25
Number of Products by Molecule Types, H2 2015 27
Number of Products by Stage and Molecule Types, H2 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report